Search a popular “natural GLP-1” or weight-loss supplement and get an honest evidence grade (A–D), a one-line verdict, what the human evidence actually shows, and a link to our full review. Every grade is pulled straight from that review's conclusion — this is a consumer-reports-style lookup, not a sales pitch. Spoiler: none of these is a GLP-1 drug, and the grades say so.
Read before you use this
This is educational information, not medical or nutrition advice, and not a diagnosis. The grades summarize the published research as we read it; they don't account for your health, medications, or circumstances, and evidence changes over time. Dietary supplements are not regulated like drugs, doses and purity vary by brand, and even “natural” products can interact with medications or carry real risks (for example, high-dose green-tea extract and liver injury). None of these is a substitute for a prescription GLP-1 medication. Before starting any supplement — especially if you are pregnant or breastfeeding, under 18, take medications, or have a medical condition — talk to a licensed clinician or registered dietitian.
Type a supplement name or nickname. Every grade and verdict below is taken straight from our full, published review of that ingredient — nothing here is a new claim.
AStrong evidenceRobust human-trial evidence of a meaningful weight or metabolic benefit.
BModerate evidenceA real but modest effect — or strong evidence for a related endpoint (like blood sugar) rather than weight.
CWeak / mixed evidencePlausible mechanism, but human weight-loss evidence is thin, small, or inconsistent.
DNo credible evidenceNo good evidence it causes weight loss — debunked, a marketing label, or untested.
All 34 supplements — graded
B
Akkermansia
Grade B · Moderate evidence
The rare supplement-aisle microbe with real (recently strengthened) human evidence — but only for the pasteurized form and only at single-digit-pound magnitude; the live strain most often sold didn’t beat placebo, and the best result is industry-funded. A defensible premium maintenance adjunct, not near a GLP-1 drug.
What the evidence shows: A 2026 maintenance trial (90 adults) found pasteurized Akkermansia gave a ~3 kg edge over placebo over six months; a 2019 pilot improved markers; a live-strain RCT showed no overall advantage.
One of the better-evidenced picks in the metabolic aisle — genuinely strong data for blood sugar and lipids, but only a small, indirect weight effect. Reasonable metformin-adjacent support, not the “nature’s Ozempic” the hype promises (clear CYP3A4 drug interactions — ask a clinician first).
What the evidence shows: Meta-analyses show robust glucose and lipid improvements but only a small, significant reduction in body weight and BMI.
A genuine viscous fiber that reliably steadies post-meal blood sugar and adds fullness, but its weight effect is small-to-none and depends on a calorie deficit. The “spikes GLP-1 like Ozempic” claim is overblown.
What the evidence shows: Strong RCT and meta-analysis evidence for glycemic control and satiety; weight-loss evidence is mixed and small.
A split decision — respectable evidence for lowering blood sugar (HbA1c and fasting glucose) in diabetes and prediabetes, but no significant body-weight effect. Buy it for glycemic support, if anything, not the scale.
What the evidence shows: Meta-analyses show significant fasting-glucose and HbA1c reductions but no significant body-weight effect.
Ground flaxseed reliably increases fullness and produces a small ~1 kg weight reduction — but a controlled trial showed it does NOT actually raise GLP-1; the satiety is a fiber effect. Real but modest, best as a sustained daily habit with a deficit.
What the evidence shows: A 45-RCT meta-analysis shows ~1 kg weight and waist drop; controlled trials show fiber-driven satiety without a GLP-1 rise.
Among the few weight-loss supplements with decent backing — a real placebo-controlled few-pound effect plus a positive EFSA opinion — but it works by physically filling the stomach. A reasonable low-cost adjunct to a deficit (3 g/day with plenty of water to avoid choking).
What the evidence shows: Meta-analyses show a genuine but modest placebo-controlled weight reduction plus satiety, with EFSA-recognized weight-management support tied to dieting.
A defensible choice specifically for women with PCOS and insulin resistance, where it supports metabolic and hormonal markers with a modest weight effect via insulin sensitivity. Outside that population the case is weak.
What the evidence shows: In insulin-resistant PCOS women, low-to-moderate-quality trials show improved markers and a small BMI reduction; little meaningful evidence without PCOS or insulin resistance.
Both rest on real mechanisms (fiber→SCFAs→your own GLP-1/PYY; probiotics shift metabolism) but magnitudes are consistently modest — better satiety and gentler glucose curves, with probiotics averaging only ~0.6 kg. Useful at the margins, no rival to a GLP-1 medication.
What the evidence shows: A 15-RCT meta-analysis found probiotics produced ~0.6 kg weight loss vs placebo; fiber reliably improves satiety and glycemia but doesn’t consistently cut calories eaten.
A genuinely useful viscous fiber with solid evidence for fullness, cholesterol, and blood sugar, plus a modest few-pound weight effect. The “poor man’s Ozempic” label oversells it — it’s mechanical fiber, with no true GLP-1 effect.
What the evidence shows: Controlled trials confirm real satiety and strong LDL/glycemic benefits; meta-analysis shows small but significant weight, BMI, and waist reductions.
Whey genuinely raises your own GLP-1 and PYY after a meal — the strongest “natural GLP-1” evidence in the category — and reliably increases satiety and blunts glucose. But it’s a transient post-meal pulse with only a modest standalone weight effect.
What the evidence shows: Strong replicated trials for raising GLP-1/PYY and satiety; the weight-loss effect is modest and appetite-mediated.
Mechanically just a fiber-and-fluid drink whose genuine effect is on regularity — easing constipation and a “lighter,” de-bloated feeling that’s stool and water, not fat. It can mildly curb appetite but is no detox and nothing like a GLP-1 drug.
What the evidence shows: Strong evidence the fiber-plus-fluid eases constipation and moderate evidence for a modest fullness nudge, but only weak weight-loss evidence and none for “detox” claims.
One of the better-evidenced single appetite ingredients on a coherent serotonin mechanism, but the trials are small, decades old, un-replicated, and partly reliant on a carbidopa pairing OTC capsules lack — plus genuine serotonin-syndrome and drug-interaction risk. A modest satiety nudge at best.
What the evidence shows: Small older RCTs in obese adults found reduced food and carb intake and modest weight loss, often with calorie restriction; no modern large replication.
A textbook weak-positive — roughly a kilogram or two over placebo that analysts call too slight to matter. Its legitimate evidence-backed use is diabetic nerve pain, not the scale.
What the evidence shows: Meta-analyses find a small 0.7–2.3 kg reduction deemed clinically insignificant; better (non-weight) data for glucose, lipids, and neuropathy.
The viral 2024 trial behind “ACV melts fat” was retracted in 2025, leaving only older, smaller studies behind a modest, mostly blood-sugar-related effect. Expect a pound or two that reverses when you stop — plus real dental and throat risks.
What the evidence shows: The surviving evidence mainly shows blunted post-meal glucose; the strongest recent positive weight study is retracted and not counted.
Reliably lowers cortisol with decent stress and anxiety evidence; one small RCT in stressed adults found a few pounds lost via reduced stress-eating. The weight benefit is indirect, modest, single-trial, and conditional on stress being the driver (rare liver-injury flag).
What the evidence shows: Moderate evidence for lowering cortisol and stress; weak single-RCT weight evidence limited to stressed adults via reduced stress-eating.
Genuinely raises metabolism and fat oxidation, but only ~50–60 calories a day and only at concentrated supplement doses — sprinkling cayenne on dinner is negligible. A real-but-trivial margin effect, never a fat-burner.
What the evidence shows: A meta-analysis found ~58 kcal/day higher energy expenditure (mostly BMI ≥25) plus a small appetite reduction — far below the seasoning-sized dose threshold.
White kidney bean extract rests on a real mechanism (alpha-amylase inhibition) but the human evidence is weak and conflicting — favorable manufacturer-linked trials offset by rigorous reviews finding nothing. A minor, hit-or-miss adjunct with predictable gas and bloating.
What the evidence shows: Friendly (often industry-tied) trials show a few pounds, but the most rigorous meta-analysis found no significant weight effect and EFSA judged the evidence insufficient.
A weak lever — about a kilogram over placebo on low-quality evidence that reviewers call clinically uncertain. Its most defensible use is a modest dampening of carb cravings in specific groups, not fat-burning.
What the evidence shows: About 1.1 kg difference vs placebo of doubtful clinical importance; only small exploratory craving signals in atypical-depression and binge-eating groups.
Blood-sugar data are genuinely mixed (no reliable HbA1c benefit in the most rigorous reviews; not guideline-recommended) and the weight effect is small and inconsistent. A pleasant spice, not a treatment — cassia also carries a coumarin liver caveat.
What the evidence shows: Mixed-to-modest glycemic evidence and weak, clinically insignificant weight-loss data.
Mostly caffeine plus ingredients with small, short-lived thermogenic effects — real in a lab, barely moving the scale, no substitute for a GLP-1 drug. A few (caffeine, green tea, capsaicin) have a modest signal; others (yohimbine, L-carnitine) are unproven or risky.
What the evidence shows: No ingredient rates strong; caffeine, green tea, and capsaicin show modest effects (much of it just caffeine), while high-dose green-tea extract carries liver-injury risk.
Just a high-protein, near-zero-calorie snack that can curb appetite and swap out more caloric food. No fat-burning, no metabolism boost, nothing GLP-1-like — the weight benefit is indirect and small.
What the evidence shows: Strong evidence that protein is satiating, but only an indirect, adherence-dependent weight effect via a calorie swap.
A weak lever whose couple-of-pounds effect is largely just caffeine, and Cochrane found it non-significant. Concentrated EGCG extract is a documented cause of supplement-related liver injury — drink the tea, skip the high-dose capsule.
What the evidence shows: Catechin-plus-caffeine meta-analyses show a small effect that washes out once caffeine is accounted for; Cochrane found it non-significant.
The “sugar destroyer” effect is real — gymnemic acids block sweet taste for ~30–120 minutes and modestly cut short-term sweet intake — but human weight-loss evidence is thin and dulling sweetness can even backfire. Strong for blunting sweet taste, weak for the scale.
What the evidence shows: A lozenge experiment and a short crossover trial show reduced sweet intake and cravings, but only one small obese-patient trial and low-certainty weight/glucose meta-analyses.
A real fat-shuttle mechanism that’s largely irrelevant in already-saturated healthy people; pooled trials show only a kilogram or two in overweight or obese adults at ~2 g/day, fading over time. An adjunct nudge, never a standalone fat-burner.
What the evidence shows: A 37-trial meta-analysis found ~1 kg weight and ~2 kg fat-mass reduction mostly in overweight/obese adults, diminishing over time; near-zero in lean people.
One small short RCT backs the famous “55% less snacking” claim, with only ~1 lb weight edge, plus a plausible serotonin/mood mechanism. Maybe a mild nudge for emotional snacking; the pooled weight evidence is weak.
What the evidence shows: A single ~60-person 8-week RCT for snacking and only modest pooled weight effects; the strongest evidence is actually for mood.
A well-characterized mechanism (thylakoids slow fat digestion to raise your own GLP-1 and CCK) with solid acute satiety data, but the marquee weight and craving results lean on industry-linked trials and lack independent replication. A plausible low-risk margin tool, not a drug-like result.
What the evidence shows: Controlled studies show acute hunger and craving reduction and raised satiety hormones, but a 2025 meta-analysis found only a small, inconsistent appetite effect, with durable outcomes resting on industry-tied data.
A category built on a sleight of hand — that nudging your own GLP-1 trivially equals an Ozempic-like effect — which the evidence doesn’t support; pooled trials of supplement compounds and herbal products found no clinically meaningful weight loss. Proprietary “activator” blends are hype-tier.
What the evidence shows: Pooled RCTs of supplement compounds and herbal products show no clinically meaningful weight loss; a viral ACV trial cited for the category was retracted.
At most a pound or two over placebo — an effect reviewers call meaningless — and the best-designed RCT found nothing. Worse, it carries a documented (rarely transplant-level) liver-injury risk, making the trade a bad one.
What the evidence shows: The best RCT showed no benefit; meta-analyses show a marginal ~1–2 lb effect against a real hepatotoxicity signal.
A marketing label, not a drug — they contain zero actual GLP-1 and can’t replicate the medication. At best a berberine/fiber/probiotic chew, usually under-dosed and priced at a candy premium.
What the evidence shows: The gummy-as-GLP-1-drug claim has no evidence; the underlying ingredients top out at modest effects and the format typically under-doses them.
Can’t work as basic skin physics — GLP-1 peptides (~3,000–4,800 Da) can’t cross intact skin (which passes molecules under ~500 Da), which is exactly why these drugs are injected. Most “GLP-1 patches” contain no GLP-1 anyway.
What the evidence shows: Every transdermal patch claim grades none — no peptide that size crosses skin, no PK data for berberine patches, and no trial showing a patch causes weight loss.
Mostly marketing — no pill, tea, or food meaningfully speeds resting metabolism, which actually slows as you lose weight. The only honest levers are protein, preserving muscle, and everyday movement.
What the evidence shows: Booster pills, detox teas, L-carnitine, and “metabolism foods” grade none; the real levers are dietary protein and NEAT, with caffeine/green tea/capsaicin offering only small fading nudges.
No credible evidence it causes weight loss — pink salt is chemically near-identical to table salt with no fat-burning mechanism, and added sodium works against blood-pressure and bloating goals. Also a notorious hook for fake-celebrity “natural Ozempic” scam funnels.
What the evidence shows: Salt-for-weight-loss and “trace mineral” benefits grade none; the only real signal belongs to the water (a pre-meal glass), not the salt.
No human trial shows sea moss causes weight loss; its only plausible effect is a small fiber-and-fullness nudge. The fat-loss data marketers cite belongs to fucoxanthin from a different seaweed, and its high, variable iodine can disrupt the thyroid.
What the evidence shows: Zero randomized weight-loss evidence; only a weak fiber mechanism plus real iodine and heavy-metal safety concerns.
They drop the scale fast, but it’s water, not fat, and it returns on rehydration — the temporary weight-cut trick combat athletes use. Useless for fat loss and they risk dehydration and dangerous electrolyte shifts.
What the evidence shows: Diuretics only lower water weight (which returns); no fat loss, with strong evidence of dehydration and electrolyte risks including hyponatremia.
How the grades are set. This is a lookup of our own published reviews, not a new analysis. Each grade reconciles that article's conclusion: A = robust human-trial weight-loss benefit; B = a real but modest effect, or strong evidence for a related endpoint like blood sugar; C = weak, mixed, or preliminary; D = no credible evidence, debunked, or a marketing label. No supplement here earns an A — none of these is a GLP-1 drug, and we won't pretend otherwise.
Go deeper than a grade
A letter is the summary; the reasoning is in the reviews. Start with these:
Each grade is taken from our own full review of that supplement, reconciling the article's conclusion. A = robust human-trial weight-loss benefit; B = a real but modest effect, or strong evidence for a related endpoint like blood sugar; C = weak, mixed, or preliminary; D = no credible evidence, debunked, or a marketing label. We don't generate new claims here — it's a lookup of what we already published.
Why doesn't anything get an A?
Because none of these is a GLP-1 drug. The best-evidenced supplements — berberine, psyllium, glucomannan, akkermansia — top out at a modest weight effect or strong data for a related endpoint such as blood sugar, which is a B. Reserving A for drug-level randomized-trial weight loss keeps the grades honest.
Are 'natural GLP-1' supplements the same as Ozempic or Wegovy?
No. GLP-1 medications are injected peptide drugs with large randomized-trial weight loss. Supplements may nudge your own GLP-1 or add fiber and fullness, but the effects are far smaller and the category is not a substitute for a prescription GLP-1 medication.
What about the apple cider vinegar study everyone cites?
The viral 2024 apple cider vinegar weight-loss trial was retracted in 2025, so we do not count it as evidence. ACV grades C on the surviving, older and smaller studies, which mostly show a modest blood-sugar effect rather than fat loss.
Is this medical advice?
No. This is educational information only, not medical or nutrition advice, and not a substitute for care from a licensed clinician or registered dietitian. Talk to a professional before starting a supplement, especially if you are pregnant or breastfeeding, under 18, take medications, or have a medical condition.
Method. This checker is a lookup over Metabolic Pantry's own published, evidence-first reviews — each supplement's grade and verdict reconcile that article's conclusion (its analysis of the trials, its FAQ, and its evidence-tier figure where present). It introduces no new claims. The retracted 2024 apple cider vinegar trial is treated as withdrawn and is not counted as positive evidence. This tool is informational and educational only — it is not medical or nutrition advice, not a diagnosis, and not a substitute for care from a licensed clinician or registered dietitian. It runs entirely in your browser; nothing is sent to a server or stored.